Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Actively Recruiting
Led by Goethe University · Updated on 2025-04-29
220
Participants Needed
85
Research Sites
N/A
Total Duration
Researchers are evaluating treatments for adults aged 18 to 65 with newly diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph ALL. This phase 2 multicenter trial, sponsored by Goethe University, aims to compare the current standard treatment of Imatinib plus low-dose chemotherapy with Ponatinib plus chemotherapy. It also seeks to explore different treatment strategies based on patients molecular response to therapy, including the use of Blinatumomab and the role of stem cell transplantation. Participants receive either Imatinib 600 mg once daily or Ponatinib 45 mg once daily reduced to 30 mg after induction, both combined with low-dose chemotherapy during induction and consolidation phases. Patients with a good molecular response are randomized to either end therapy with indication for stem cell transplantation or continue treatment with TKI, chemotherapy, and Blinatumomab. Those with poor molecular response receive Blinatumomab followed by end of therapy and transplantation indication. Stem cell transplantation itself is not part of the trial. During the study, participants undergo molecular evaluations for BCR-ABL1, regular monitoring of blood counts, and assessments of treatment response. Researchers measure overall survival in molecular complete remission patients receiving TKI-chemotherapy-Blinatumomab versus standard end of therapy with transplantation indication. Safety and remission rates are also tracked. The study involves follow-up for up to four years from randomization to assess long-term outcomes and treatment effects.
CONDITIONS
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
N
Nicola Goekbuget, MD
F
Fabian Lang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Goethe University
Lead Sponsor
Deutsche Leukämie- & Lymphom-Hilfe
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 4 years from randomization
Participants receive either Imatinib or Ponatinib combined with low-dose chemotherapy as initial treatment. Depending on molecular response, some participants receive Blinatumomab cycles and continue with chemotherapy and tyrosine kinase inhibitors, while others proceed towards stem cell transplantation.
Multiple visits for treatment and monitoring throughout the treatment period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Goethe University
Lead Sponsor
Deutsche Leukämie- & Lymphom-Hilfe
Collaborating Sponsor